Buy HIMS by Nov 22, 2025.

**Background:** * **GLP-1 Demand :** Wegovy (Novo) and Zepbound are dominating the branded weight-loss markets but face demand that they cannot keep up with. * **Trump’s Legacy:** Under the Trump administration, rules around drug compounding were clarified, allowing pharmacies to fill gaps during shortages. Now, these policies will be central to ongoing lawsuits ([see this executive order](https://trumpwhitehouse.archives.gov/presidential-actions/executive-order-ensuring-essential-medicines-medical-countermeasures-critical-inputs-made-united-states/?utm_medium=email&utm_source=ncl_amplify&utm_campaign=230724-agenda47_returning_production_of_essential_medicines_back_to_america_and_ending_bidens_pharmaceutical_shortages&utm_content=ncl-7CGRrbfsEr&_nlid=7CGRrbfsEr&_nhids=NJKu9Lb)). * **FDA issues:** The FDA pulled tirzepatide (Zepbound/Mounjaro) from the shortage list in October but has since walked back on this after legal …